EntreMed to Participate in Anti-Angiogenesis Panel at BIO CEO Conference
February 18, 2005
ROCKVILLE, MD, Feb 18, 2005—EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, today announced James S. Burns, President & CEO, will participate in a panel discussion on “Starving Cancer” at the 2005 Biotechnology Industry Organization (BIO) CEO & Investor Conference being held February 23-24, 2005 in New York. The panel will be held February 24th from 9:30 a.m. to 10:55 a.m.
Mr. Burns will join biotechnology industry leaders to discuss the latest approaches and clinical progress of both anti-angiogenesis and vascular targeting agents. Starving tumors and the blood vessels that nourish them has been the focus of breakthrough discoveries by many companies and leading cancer researchers. EntreMed’s lead compound, PanzemÂ® NCD (2-methoxyestradiol or 2ME2) and its second generation 2ME2 analog, ENMD-1198, both work through multiple mechanisms that attack tumor cells directly, as well as the blood vessels that nourish them.
The panel discussion will include an overview of the current state of angiogenesis, an overview from participating companies, and a question and answer session immediately following the formal presentations. The focus session will be web cast and will be available on the Company’s web site at http://www.entremed.com and the conference web site at http://www.ceo.bio.org approximately 24 hours after the event.
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. PanzemÂ® (2-Methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for advanced cancer, as well as in preclinical development for indications outside of oncology. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation—processes vital to the treatment of cancer and other diseases. The Company’s expertise has also led to the discovery of new molecules, including analogs of 2ME2, peptides of tissue factor pathway inhibitor (TFPI), and inhibitors of fibroblast growth factor-2 (FGF-2) and proteinase activated receptor-2 (PAR-2). EntreMed is developing these potential drug candidates for either in-house advancement or external partnering. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission. PanzemÂ® NCD is in clinical trials and has not been approved by the Food and Drug Administration.
Forward Looking Statements
This release contains, and other statements that EntreMed may make may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are typically identified by words or phrases such as “believe,” “feel,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “target,” “assume,” “goal,” “objective,” “plan,” “remain,” “seek,” “trend,” and variations of such words and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” “may,” or similar expressions. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and EntreMed assumes no duty to update forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in EntreMed’s Securities and Exchange Commission filings under “Risk Factors,” including risks relating to EntreMed’s need for additional capital and the uncertainty of additional funding; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of PanzemÂ® NCD, dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CASI Pharmaceuticals, Inc.